Lorraine Lipscombe
Lorraine Lipscombe | |
|---|---|
| Born | Montreal, Quebec, Canada |
| Academic background | |
| Education | BSc, psychology, Concordia University MD, 1998, McGill University MSc, Clinical Epidemiology, Health Policy, Management and Evaluation, 2005, University of Toronto |
| Thesis | Diabetes mellitus and the risk of postmenopausal breast cancer: a retrospective population-based cohort study. (2005) |
| Academic work | |
| Institutions | University of Toronto |
Lorraine L. Lipscombe is a Canadian endocrinologist. In 2021, Lipscombe was appointed the director of the University of Toronto's Novo Nordisk Network for Healthy Populations.
Early life and education[edit]
Born and raised in Montreal, Lipscombe completed her Bachelor of Science degree in psychology at Concordia University where she helped complete research on how hormones affect maternal behaviour in rats.[1] She then completed her medical degree at McGill University in 1998 before enrolling at the University of Toronto for Internal Medicine and Endocrinology residency training, followed by a Master's degree in Clinical Epidemiology, Health Policy, Management, and Evaluation.[2] While completing her master's degree, Lipscombe discovered that there was a bidirectional relationship between breast cancer and diabetes. She also found that women with diabetes received fewer mammograms and had a higher mortality and more advanced stage of breast cancer at diagnosis.[1]
Career[edit]
Following her MSc, Lipscombe joined the Department of Endocrinology at Women's College Hospital (WCH) in 2006.[1] Lipscombe is a professor in the University of Toronto Faculty of Medicine and was director of the Division of Endocrinology at WCH from 2017 to 2021.[3] While working in these roles, Lipscombe developed a program to assist women with gestational diabetes which included lifestyle coaching on healthy eating and physical activity.[4] She also received funding for her research into why health outcomes were worse for cancer patients who also had diabetes.[5] In 2007, Lipscombe was awarded a Clinician Scientist Award from Diabetes Canada, followed by a New Investigator Award from the Canadian Institutes for Health Research in 2012, and a Diabetes Investigator Award from Diabetes Canada in 2018.
In 2021, Lipscombe was appointed the director of the University of Toronto's Novo Nordisk Network for Healthy Populations.[6]
References[edit]
- ^ a b c Treleaven, Sarah (November 1, 2017). "How Dr. Lorraine Lipscombe is creating better care for women with diabetes". Women of Influence. Archived from the original on 2022-02-11. Retrieved February 11, 2022.
- ^ "LORRAINE LIPSCOMBE, MD, MSC, FRCPC". Women's College Hospital. Archived from the original on 2022-02-11. Retrieved February 11, 2022.
- ^ "Starting diabetes prevention during pregnancy". Diabetes Canada. October 1, 2021. Archived from the original on 2022-02-11. Retrieved February 11, 2022.
- ^ "WCRI receives more than $2.4 million in new research funding". Women's College Hospital. June 7, 2017. Archived from the original on 2022-02-11. Retrieved February 11, 2022.
- ^ "Research examines healthcare experience for cancer patients who also have diabetes". OICR. November 22, 2016. Archived from the original on 2022-02-11. Retrieved February 11, 2022.
- ^ Eligh, Blake (June 18, 2021). "U of T endocrinologist Lorraine Lipscombe to lead 'powerhouse' diabetes research network". University of Toronto. Archived from the original on 2022-02-11. Retrieved February 11, 2022.
| Authority control databases: Academics |
|---|
